CES1 Crossover Trial of Clopidogrel and Ticagrelor

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 111 participants.

Also called NCT03161678

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose basic science
Phase
Phase 4
Enrolled
  • 111 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03161678
Other papers using this trial's data
  • Randomized evaluation of the loss-of-function carboxylesterase 1 (CES1) G143E variant on clopidogrel and ticagrelor pharmacodynamics Clinical and translational science, 2024-11 DOI, PubMed 39576732, PMC11583987 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03161678. Randomized; no masking; primary purpose basic science. Start 2017-08-22 (actual); primary completion 2022-12-12 (actual). Results posted on 2024-05-06.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
CES1 Crossover Trial of Clopidogrel and Ticagrelor
Condition
Thrombosis
Condition
Platelet Dysfunction
Intervention (Drug)
Clopidogrel
Intervention (Drug)
Ticagrelor
Lead sponsor
University of Maryland, Baltimore (class: other)

Record details

Record id
cardio:ct-nct03161678
Content hash
c08edf44d835001f9548237282b8e15a039bb5bdc8f07df98b1df7a86c38e0f3